8 active not recruiting. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Active not recruiting 8 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Bone Scan: new trials by email Literature Review of Bone Scan trials Research Report on Bone Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-26 |
| A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | Children's Oncology Group | 113 | 2021-09-14 | 2026-07-30 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 184 | 2021-06-28 | 2026-10-26 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 586 | 2020-04-16 | 2026-08-17 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Biospecimen Collection, Bone Scan, Cabozantinib - Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1175 | 2019-06-07 | 2026-10-26 |
| Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Bone Scan, Cisplatin, Clinical Observation - EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 924 | 2014-07-01 | 2026-10-13 |
Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Epstein-Barr Virus Infections (1) · Lymphatic Metastasis (1) · Nasopharyngeal Carcinoma (1) · Rhabdomyosarcoma (1) · Rhabdomyosarcoma, Alveolar (1) · Rhabdomyosarcoma, Embryonal (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1)
National Cancer Institute (NCI) (4) · NRG Oncology (3) · Children's Oncology Group (1)
United States (8) · Canada (5) · Puerto Rico (4) · Australia (2) · China (1) · Hong Kong (1) · Saudi Arabia (1) · Singapore (1) · Taiwan (1)
Matthew Ingham (1) · Nancy Y Lee (1) · Paul L Nguyen (1) · Ronald C Chen (1) · Sarmad Sadeghi (1) · Shilpa Gupta (1) · Tian Zhang (1) · Wendy Allen-Rhoades (1)
PMID 35304832, PMID 35383907, PMID 38421243, PMID 39938471
U10CA180821 (3), U10CA180868 (3), U10CA021661 (1), U10CA180886 (1), U10CA180888 (1)